March 2014 in “The Journal of Urology” This study observed that long-term treatment with 5ARIs in men with LUTS/BPH was linked to worsening sexual function, whereas doxazosin alone had minimal negative impact.
33 citations
,
January 2009 in “Journal of Cutaneous and Aesthetic Surgery” This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.
71 citations
,
November 2012 in “Expert Opinion on Drug Safety” This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.
February 2024 in “The Journal of Sexual Medicine” This study suggests that 5α-reductase inhibitors do not significantly affect male reproductive function but may require caution in men with oligospermia or ejaculatory issues.
11 citations
,
August 2014 in “Current Urology Reports” This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.
1 citations
,
August 2015 in “Current Sexual Health Reports” This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.
17 citations
,
January 2013 in “Our Dermatology Online” This study concluded that mesotherapy with a dutasteride-containing solution was the most effective option for treating androgenetic alopecia in males, promoting hair growth and reducing hair loss.
15 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” This review discusses the effects of 5ARI drugs on male reproductive parameters, reporting potential decreases in sperm count and motility more significantly in men with pre-existing oligozoospermia, but does not provide fertility outcomes.
26 citations
,
August 2016 in “Translational Andrology and Urology” This review discusses the impact of medical and surgical treatments for LUTS/BPH on ejaculatory function, highlighting that most treatments negatively affect it, except for some minimally invasive surgical therapies and specific medical therapies.
2 citations
,
January 2023 in “Sexual Medicine” This study found that the MTCK, a masturbation aid, significantly improved intravaginal ejaculation latency time and some related sexual function scores in men with premature ejaculation after 8 weeks of use.
8 citations
,
August 2021 in “Fertility and Sterility” This review discusses the potential risks of ejaculatory dysfunction associated with both medical and surgical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and their implications for male fertility, but it reports no new clinical results.
January 2017 in “Indian journal of sexually transmitted diseases and AIDS” Finasteride, a hair loss drug, can cause sexual side effects like erectile dysfunction in 2.1%-3.8% of users, but these usually go away with time or if the drug is stopped. Despite this, its impact on sexual function is minimal for most men.
34 citations
,
December 2021 in “Journal of Clinical Medicine” This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.
4 citations
,
June 2025 in “Current Urology Reports” This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.
October 2017 in “The Journal of Urology” Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.
1 citations
,
October 2022 in “Springer eBooks” This review discusses the roles of hormonal pathways in regulating male sexual function, particularly highlighting the impact of testosterone, and reports no new research findings.
March 2024 in “The journal of sexual medicine” This case study observed that in four middle-aged men with ejaculation disorders, therapy with human chorionic gonadotropin (hCG) alone or combined with recombinant follicle-stimulating hormone (rFSH) improved sexual desire, semen volume, and various other symptoms, although some experienced elevated estradiol levels and hair loss.
35 citations
,
January 2012 in “The Journal of Sexual Medicine” This review examines various androgen deprivation therapy methods for advanced prostate cancer, highlighting benefits and potential cardiovascular and sexual adverse effects, but reports no new clinical results.
72 citations
,
April 2008 in “The Journal of urology/The journal of urology” This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.
February 2005 in “The Journal of Urology” This article evaluates sexual function using the International Index of Erectile Function in people taking finasteride for androgenetic alopecia but does not present new findings.
393 citations
,
November 2000 in “Archives of General Psychiatry” This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.
29 citations
,
July 2012 in “The Journal of Sexual Medicine” In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.
31 citations
,
September 2008 in “International Journal of Andrology” This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.
24 citations
,
December 2013 in “Sexual medicine reviews” This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.
39 citations
,
January 2012 in “Indian Dermatology Online Journal” This article examines the evidence regarding finasteride's sexual side effects and offers recommendations for patient counseling but reports no new clinical findings.
April 2024 in “International journal of impotence research” Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.
May 2017 in “Urology and andrology” Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.
50 citations
,
September 2016 in “The Journal of Clinical Endocrinology and Metabolism” This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.